MIRUM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.22 USD | +1.67% |
|
+4.92% | -11.18% |
| May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
| May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 553.3 | 510.7 | 486.2 | 718.5 | 1,376 | 1,236 | - | - |
| Enterprise Value (EV) 1 | 553.3 | 510.7 | 329.7 | 566.8 | 1,396 | 1,142 | 1,147 | 822.2 |
| P/E ratio | -5.35 x | -4.27 x | -5.76 x | -4.85 x | -7.49 x | -19.7 x | 502 x | 24.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 25.4 x | 9.32 x | 7.38 x | 3.91 x | 3.05 x | 2.39 x |
| EV / Revenue | - | - | 17.2 x | 7.36 x | 7.49 x | 3.61 x | 2.83 x | 1.59 x |
| EV / EBITDA | - | - | -1.91 x | -4.43 x | - | -17.5 x | -168 x | 17.8 x |
| EV / FCF | -14 x | -5.75 x | -2.48 x | -4.71 x | -19.6 x | -35.5 x | 154 x | 15.8 x |
| FCF Yield | -7.16% | -17.4% | -40.3% | -21.2% | -5.09% | -2.82% | 0.65% | 6.35% |
| Price to Book | - | - | 4.06 x | 4.67 x | - | 6.33 x | 8.33 x | 9.39 x |
| Nbr of stocks (in thousands) | 22,567 | 29,250 | 30,482 | 36,848 | 46,614 | 47,133 | - | - |
| Reference price 2 | 24.52 | 17.46 | 15.95 | 19.50 | 29.52 | 26.22 | 26.22 | 26.22 |
| Announcement Date | 3/12/20 | 3/9/21 | 3/9/22 | 3/8/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 19.14 | 77.06 | 186.4 | 316 | 405.8 | 516.1 |
| EBITDA 1 | - | - | -172.8 | -128 | - | -65.38 | -6.828 | 46.09 |
| EBIT 1 | -54.74 | -104.3 | -173.4 | -131.2 | -106.6 | -75.97 | -3.613 | 82.79 |
| Operating Margin | - | - | -906.12% | -170.28% | -57.22% | -24.04% | -0.89% | 16.04% |
| Earnings before Tax (EBT) 1 | -52.53 | -103.3 | -83.95 | -142.1 | -159.9 | -76.16 | -1.379 | 94.23 |
| Net income 1 | -52.55 | -103.3 | -83.99 | -135.7 | -160.9 | -66.04 | -1.534 | 48.17 |
| Net margin | - | - | -438.85% | -176.05% | -86.33% | -20.9% | -0.38% | 9.33% |
| EPS 2 | -4.580 | -4.090 | -2.770 | -4.020 | -3.940 | -1.329 | 0.0522 | 1.076 |
| Free Cash Flow 1 | -39.64 | -88.85 | -132.8 | -120.4 | -71.05 | -32.2 | 7.459 | 52.19 |
| FCF margin | - | - | -693.81% | -156.26% | -38.12% | -10.19% | 1.84% | 10.11% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 113.23% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 108.34% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/9/21 | 3/9/22 | 3/8/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.138 | 12.89 | 17.48 | 18.78 | 27.91 | 31.6 | 37.5 | 47.72 | 69.55 | 69.22 | 75.4 | 82.13 | 88.76 | 90.17 | 98.33 |
| EBITDA 1 | -45.23 | -32.39 | -30.84 | -31.44 | - | -25.81 | - | - | - | -20.8 | -13.06 | -5.363 | -1.106 | - | - |
| EBIT 1 | -45.58 | -32.74 | -31.44 | -32.88 | -34.16 | -27.15 | -24.27 | -25.15 | -30.08 | -26.47 | -22.68 | -16.82 | -12.9 | -7.828 | -0.642 |
| Operating Margin | -1,452.36% | -253.92% | -179.83% | -175.09% | -122.41% | -85.92% | -64.73% | -52.69% | -43.24% | -38.24% | -30.08% | -20.48% | -14.53% | -8.68% | -0.65% |
| Earnings before Tax (EBT) 1 | 57.56 | -36.6 | -33.49 | -35.69 | -36.29 | -29.93 | -73.72 | -23.34 | -32.92 | -24.66 | -23.58 | -16.61 | -14 | -8.793 | -1.614 |
| Net income 1 | 57.55 | -36.61 | -26.92 | -35.71 | -36.43 | -30.13 | -74.04 | -23.59 | -33.15 | -25.28 | -20.38 | -14.02 | -7.847 | -8.722 | -1.582 |
| Net margin | 1,833.84% | -283.94% | -153.98% | -190.13% | -130.55% | -95.35% | -197.45% | -49.42% | -47.66% | -36.52% | -27.03% | -17.07% | -8.84% | -9.67% | -1.61% |
| EPS 2 | 1.910 | -1.170 | -0.8400 | -1.020 | -0.9900 | -0.8000 | -1.940 | -0.5700 | -0.6300 | -0.5400 | -0.4411 | -0.3064 | -0.1752 | -0.1800 | -0.0350 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/22 | 5/5/22 | 8/4/22 | 11/9/22 | 3/8/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/28/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 20.1 | - | - | - |
| Net Cash position 1 | - | - | 157 | 152 | - | 93.7 | 88.7 | 414 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -39.6 | -88.9 | -133 | -120 | -71.1 | -32.2 | 7.46 | 52.2 |
| ROE (net income / shareholders' equity) | - | - | -57.5% | -103% | -82.4% | -34.6% | -4.31% | -8.74% |
| ROA (Net income/ Total Assets) | - | - | -31.4% | -41.9% | -32.2% | -15.2% | -15.9% | -12.3% |
| Assets 1 | - | - | 267.8 | 323.8 | 499.8 | 435.2 | 9.634 | -390.1 |
| Book Value Per Share 2 | - | - | 3.930 | 4.180 | - | 4.140 | 3.150 | 2.790 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.28 | - | - | 0.28 | 0.11 | 0.23 | 0.23 | 0.23 |
| Capex / Sales | - | - | - | 0.36% | 0.06% | 0.07% | 0.06% | 0.04% |
| Announcement Date | 3/12/20 | 3/9/21 | 3/9/22 | 3/8/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
26.22
USD
Average target price
48
USD
Spread / Average Target
+83.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.18% | 1.24B | |
| +64.23% | 62.59B | |
| -2.31% | 41.18B | |
| +45.66% | 40.29B | |
| -8.29% | 27.9B | |
| +11.97% | 26.21B | |
| -21.16% | 19.09B | |
| +7.54% | 13.08B | |
| +25.72% | 12.26B | |
| +27.17% | 12.05B |
- Stock Market
- Equities
- MIRM Stock
- Financials Mirum Pharmaceuticals, Inc.
